French health body to say mRNA vaccine should be used as second dose after AstraZeneca
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
TUESDAY, MAY 17, 2022
TUESDAY, MAY 17, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
French health body to say mRNA vaccine should be used as second dose after AstraZeneca

Coronavirus chronicle

Reuters
09 April, 2021, 09:20 am
Last modified: 09 April, 2021, 09:20 am

Related News

  • Macron suggests new European entity
  • France's Macron sworn in for second term as president
  • Armed robbers strike Chanel jewellery store in Paris and flee on motorbikes
  • France and India call for immediate end to Ukraine hostilities
  • Main negotiators reach 'outcome' on Covid vaccine IP waiver, WTO says

French health body to say mRNA vaccine should be used as second dose after AstraZeneca

Two mRNA vaccines, one from Pfizer and BioNTech and one from Moderna, are approved for use in France

Reuters
09 April, 2021, 09:20 am
Last modified: 09 April, 2021, 09:20 am
French health body to say mRNA vaccine should be used as second dose after AstraZeneca

France's top health body will on Friday say that recipients of a first dose of AstraZeneca's traditional Covid-19 vaccine who are under 55 should get a second shot with a new-style messenger-RNA vaccine, two sources aware of the plans said on Thursday.

Reuters had reported on Wednesday that the Haute Autorite de la Sante (HAS), in charge of setting out how vaccines approved by the European Medicines Agency (EMA) should be used in France, was contemplating this possibility.

The HAS has now decided to proceed with the plan, the two sources said. Two mRNA vaccines, one from Pfizer and BioNTech and one from Moderna, are approved for use in France.

Messenger RNA vaccines prompt the human body to make a protein that mimics part of the virus, triggering an immune response, while viral vector vaccines such as AstraZeneca's use a common cold virus to carry DNA instructions for doing the same thing.

An HAS spokeswoman had no comment.

Vaccination programmes have stuttered in Europe and elsewhere in the last month, since a very few mostly young recipients of the AstraZeneca shot were found to have suffered extremely unusual blood clots, leading some countries to suspend its use as a precaution.

Most have resumed using the shot, although some have done so with age restrictions.

In France, the HAS advised on March 19 that only people aged 55 and over should receive the AstraZeneca vaccine, which had already been given to 500,000 people as a first dose.

While the numbers are small compared with the tens of millions being inoculated across the EU, a decision to give a different booster shot would be significant because the approach has not been tested in late-stage human trials.

Germany was the first European country to recommend that people under 60 who have had a first AstraZeneca shot should receive a different product for their second dose.

Some experts say that, because all the vaccines target the same outer "spike" protein of the virus, they could be complementary. But there is no evidence that this approach will be as effective.

Top News

covid-19 vaccine / France

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Are banks only gainers from dollar crisis?
    Are banks only gainers from dollar crisis?
  • PK Halder wants to return home
    PK Halder wants to return home
  • Exporters for continuation of 0.5% source tax for 5 years 
    Exporters for continuation of 0.5% source tax for 5 years 

MOST VIEWED

  • Customers wait in front of a restaurant in Beijing, China April 15, 2022. REUTERS/Tingshu Wang/Files
    China's economy skids as lockdowns hit factories, retailers
  • A medical worker in a protective suit collects a swab from a resident at a makeshift nucleic acid testing site inside a residential compound under lockdown, amid the coronavirus disease (COVID-19) outbreak in Shanghai, China April 14, 2022. REUTERS/Xihao Jiang
    Shanghai aims for return to normal life from 1 June
  • South Korea's new President Yoon Suk-yeol signs a document as he works at the new Presidential office in Seoul, South Korea, May 10, 2022. Yonhap via REUTERS/File Photo
    S Korea says it will spare no effort to help North Korea amid Covid outbreak
  • North Korean leader Kim Jong Un wears a face mask amid the coronavirus disease (Covid-19) outbreak, while inspecting a pharmacy in Pyongyang, in this undated photo released by North Korea's Korean Central News Agency (KCNA) on May 15, 2022. KCNA via REUTERS
    Kim Jong Un orders North Korea military to 'stabilise' drug supply amid Covid outbreak
  • North Korea reports 15 more suspected Covid-19 deaths
    North Korea reports 15 more suspected Covid-19 deaths
  • Residents line up for nucleic acid tests during lockdown, amid the coronavirus disease (Covid-19) pandemic, in Shanghai, China, May 9, 2022. REUTERS/Aly Song
    Locked-down Shanghai to start gradually reopening malls, other businesses

Related News

  • Macron suggests new European entity
  • France's Macron sworn in for second term as president
  • Armed robbers strike Chanel jewellery store in Paris and flee on motorbikes
  • France and India call for immediate end to Ukraine hostilities
  • Main negotiators reach 'outcome' on Covid vaccine IP waiver, WTO says

Features

Bitcoin, by far the largest cryptocurrency, is a terrible substitute for government-issued money. Photo: Reuters

Crypto’s wild week offers a much-needed warning

12h | Panorama
Karst Stone Paper Journal: Write on indestructible stone paper

Karst Stone Paper Journal: Write on indestructible stone paper

13h | Brands
Pesky bugs do not stand a chance against this automatic indoor insect trap

Pesky bugs do not stand a chance against this automatic indoor insect trap

13h | Brands
Wazeenah: Turning furniture into a canvas

Wazeenah: Turning furniture into a canvas

12h | Brands

More Videos from TBS

Finland, Sweden decide to join NATO

Finland, Sweden decide to join NATO

4h | Videos
Where you can swim for Tk5

Where you can swim for Tk5

6h | Videos
Cultural activists pay tribute to Hassan Arif

Cultural activists pay tribute to Hassan Arif

9h | Videos
How PK Halder becomes a scamster

How PK Halder becomes a scamster

9h | Videos

Most Read

1
Representative Photo: Pixabay.
Bangladesh

Microplastics found in 5 local sugar brands

2
Mushfiq Mobarak. Photo: Noor-A-Alam
Panorama

Meet the Yale professor who anchors his research in Bangladesh and scales up interventions globally

3
Impact of falling taka against US dollar
Banking

Taka losing more value as global currency market volatility persists

4
Govt tightens belt to relieve reserve
Economy

Govt tightens belt to relieve reserve

5
Union Capital asked to return Tk100cr FDR to BATBC 
Banking

Union Capital asked to return Tk100cr FDR to BATBC 

6
How Bangladesh can achieve edible oil self-sufficiency with local alternatives
Bazaar

How Bangladesh can achieve edible oil self-sufficiency with local alternatives

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab